featured-image

Pixelimage/iStock via Getty Images GSK ( NYSE: GSK ) announced Tuesday that depemokimab, its experimental therapy for severe asthma, reached the primary endpoints in two late-stage studies, indicating statistically significant and clinically meaningful reductions in asthma attacks in adults and adolescents. Citing topline data from its SWIFT-1 and SWIFT-2 trials, the British drugmaker said depemokimab given as adjunctive therapy with a six-month dosing schedule reduced the annualized rate of asthma attacks over 52 weeks. SWIFT-1 and SWIFT-2 are designed to evaluate depemokimab against placebo in 375 and 380 patients, respectively, with severe asthma with type 2 inflammation.

The frequency and severity of treatment-emergent adverse events in both trials were similar across both study arms. GSK’s ( GSK ) Phase 3 program for depemokimab includes a trial involving patients with severe asthma who are switched from the company’s asthma therapy, mepolizumab, branded as Nucala, or bevacizumab, another asthma drug marketed by AstraZeneca ( AZN ) as Fasenra. More on GSK GSK plc (GSK) Q1 2024 Earnings Call Transcript GSK Trades At Low Price Multiples, But Its Pipeline Needs To Improve GSK plc (GSK) TD Cowen 44th Annual Health Care Conference (Transcript) GSK faces another Zantac whistleblower lawsuit Novo Nordisk, J&J lead R&D rankings in big pharma: report.



Back to Health Page